Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

The diabetes management space just got a whole lot more interesting. FDA has cleared Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous monitoring sensors for integration with ...

Abbott Laboratories says its not afraid that GLP-1 drugs will hurt the continuous glucose monitor (CGM) market. Abbott on Thursday released an analysis of patients' use of increasingly popular drugs ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...

Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...